Biogen Idec and Elan Corporation, plc today announced 28 company-supported Tysabri ® (natalizumab) presentations at the 5 th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS and ACTRIMS), held in Amsterdam, the Netherlands.
Key data indicated patients on Tysabri experienced reduced annualized relapse rates (ARR), particularly in those treated with Tysabri early in the course of their disease. Data also indicated a long-term benefit for patients who had achieved freedom from disease activity early in their treatment course. Data from a separate study showed Tysabri-treated patients experienced improved incontinence-related quality of life (QOL). Additional data sets were presented further supporting Biogen Idec´s and Elan´s efforts to stratify the risk of progressive multifocal leukoencephalopathy (PML) in Tysabri-treated patients.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1768
